• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAA
Click for more information
4.00% 24.0¢

PHARMAUST LIMITED - Charts / Financials

Market Cap $94.80M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for... PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.More

refresh Created with Sketch. REFRESH
Last update - 15.58pm 26/04/2024 (20 minute delay) ?
Day
Open 25.0¢   Day High 25.0¢   Day Low 23.5¢
Daily Volume 586133
Bids   Sellers
Number Price Volume   Number Price Volume
2 24.0¢ 12010   1 24.5¢ 70000

Directors & Senior Management

Mr. John Clark Interim Chief Executive Officer
Dr. Michael Thurn Chief Executive Officer
Ms. Fiona Milner General Manager - Epichem Pty Ltd
Mr. Robert Charles Bishop Executive Director
Mr. Sam Michael Wright Company Secretary, Non-Executive Independent Director
Dr. Roger Aston Non-Executive Chairman of the Board
Mr. Neville John Bassett Non-Executive Director
Dr. Thomas Duthy Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
24.0¢ 		Change
-0.010(4.00%) 		Mkt cap ! $94.80M
Open High Low Value Volume
25.0¢ 25.0¢ 23.5¢ $140.9K 586.1K

Buyers (Bids)

No. Vol. Price($)
2 12010 24.0¢
 

Sellers (Offers)

Price($) Vol. No.
24.5¢ 70000 1
View Market Depth
Last trade - 16.10pm 26/04/2024 (20 minute delay) ?
Last
23.5¢ 		  Change
-0.010 ( 4.08 %)
Open High Low Volume
24.0¢ 24.5¢ 23.5¢ 164909
Last updated 15.58pm 26/04/2024 ?

Top Stories

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
Regal copper grades at Gascoyne play see shares jump 33% for Augustus Augustus Minerals is reporting high grade copper rock chip results at Ti-Tree in WA based on recent fieldwork.
Raiden’s jump into lithium territory in WA’s Pilbara echoes earlier journey by Azure In its bid to define a noteworthy lithium deposit in WA’s Pilbara region, Raiden Resources is following in the footsteps of another explorer.
Week 17 Wrap: BHP-Anglo deal helps push down ASX; US data of concern but AI bulls happy The big thematics and headlines that drove the ASX this week, plus, the headlines I think investors ought to be keeping eyes on.
Recharged Prospects: 'Watts' on the horizon for copper & lithium The conversation goes much deeper that this title suggests - it explores everything from projections on aluminium & manganese, to what a Donald Trump government could mean for commodities markets.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.